Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bioequivalence Study of Clopidogrel vs Plavix in Healthy Volunteers
NCT05934799Phase 1Completed
- Sponsor
- Pharmtechnology
- Start
- Jun 2023
- Primary completion
- Jul 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of clopidogrel in atherothrombosis (2 arms), sponsored by Pharmtechnology. Primary endpoints: Maximum Plasma Concentration and Area Under the Curve to Last Quantifiable Concentration. Started Jun 2023; status: completed.
02
Drugs
clopidogrel
03
Conditions
atherothrombosis
Beyond the preview
Go deeper on NCT05934799.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05934799.